Mental and Behavioral Health

A new study found that 52% of participants with treatment-refractory unipolar or bipolar depression achieved remission after 3 ketamine infusions.

After facing challenges, Biogen is discontinuing development and sales of aducanumab (Aduhelm) and focusing on lecanemab (Leqembi).

Compared to only 10% of primary and subspecialty visits, 34.5% of mental health visits took place via video in August 2023.

Investigators recommended that isotetinoin be used with extreme caution among patients with a history of mental illness in light of study findings.

Despite affecting 13 million Americans annually, existing post-traumatic stress disorder (PTSD) treatments offer modest relief and more effective approaches are needed.

Increased clinical awareness around the value of lithium monitoring was ultimately achieved.

New study findings conflict with long-understood associations between maternal depression and the postpartum period and highlight the potential need for public health policy revisions.

The NDA was submitted for investigational muscarinic antipsychotic, KarXT (xanomeline-trospium), which functions as a dual M1/M4 muscarinic acetylcholine receptor agonist within the central nervous system.

Suicides among health care professionals are estimated to occur at a higher rate than in the general public.

According to the National Community Pharmacists Association, 97% of independent pharmacy owners reported shortages of Adderall in early 2023.

Researchers hope a new study will alleviate patients and clinicians fear of prescribing stimulants for children with ADHD.

Centanafadine is a serotonin-norepinephrine-dopamine triple reuptake inhibitor.

An in-depth assessment of treatment-resistant depression therapies is explored.

The panelists provide an overview of the treatment model for treating patients with treatment-resistant depression.

Key opinion leaders illustrate treatment strategies for patients diagnosed with TRD.

Medical experts discuss the risk factors associated with TRD.

The incidence and prevalence of TRD is explored.

Megan Maroney, PharmD, BCPP, leads a discussion about the treatment landscape of TRD.

Pharmacogenetic testing and therapeutic drug monitoring are feasible in the inpatient psychiatric treatment setting.

Survey respondents indicated a lack of comfort around recommending psilocybin therapy to patients.

How can current Alzheimer disease treatments be used to best treat patients living with the disease?

There was a lower probability of initiating psycholeptics and experiencing postpartum psychiatric emergencies in study patients who continued using antidepressants

Developing innovative solutions for women with depression, accounting for differences in gender and sex, are critically important

A recent CDC report detailed the increased rates of sadness and violence among teenage girls.

United States leaders work together to create bipartisan solutions for the youth mental health crisis.

The relationship between dermatology and social media was analyzed in a poster presentation during SBS 2023 in Miami, Florida.